Elsevier

Seminars in Nephrology

Volume 29, Issue 5, September 2009, Pages 483-486
Seminars in Nephrology

Chronic Kidney Disease Epidemic: Cost and Health Care Implications in China

https://doi.org/10.1016/j.semnephrol.2009.06.012Get rights and content

Summary

Chronic kidney disease is growing as a global public health problem. With more than 1.3 billion people, China is the world's largest and most populous country. Understanding the epidemiology of chronic kidney disease in China could be helpful to predict its impact on the health care system and to establish comprehensive strategies to reduce its burden.

Section snippets

Study Concerns From a Methodologic Standpoint

There are some issues that need to be considered when evaluating the information regarding prevalent CKD in China. The first issue is the sampling method of the study population. In our own study, the prevalence of an eGFR of less than 60 mL/min/1.73 m2 in a convenient sample of 2,310 adults aged 40 years or older from one district of Beijing was 5.2%.7 In another study from a representative sample of adults in Beijing,2 the prevalence of an eGFR of less than 60 mL/min/1.73 m2 among those older

CKD: A Big Challenge in China

Although information regarding the prevalence of CKD in China is not perfectly precise, it does suggest that CKD is a big challenge to the public health system in China and deserves intense attention.

References (28)

  • L. Zhang et al.

    Community-based screening for chronic kidney disease among populations older than 40 years in Beijing

    Nephrol Dial Transplant

    (2007)
  • Y.C. Ma et al.

    Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease

    J Am Soc Nephrol

    (2006)
  • K. Reynolds et al.

    A population-based, prospective study of blood pressure and risk for end-stage renal disease in China

    J Am Soc Nephrol

    (2007)
  • M. Tozawa et al.

    Blood pressure predicts risk of developing end-stage renal disease in men and women

    Hypertension

    (2003)
  • Cited by (33)

    • CKD in China: Evolving Spectrum and Public Health Implications

      2020, American Journal of Kidney Diseases
      Citation Excerpt :

      Given the lack of corresponding national data, we extrapolated from data from the Hong Kong Diabetes Registry and estimated the potential number of Chinese mainland patients with ESKD due to DM to be approximately 1.06 million, which is much larger than the number of prevalent dialysis patients in 2015 (0.40 million).29 Because dialysis is covered by the Basic Health Insurance policy in China,30 1.06 million incident dialysis patients each year would correspond to an additional 106 billion Renminbi (RMB; about US $15.3 billion) annually. This translates to dialysis expenses of 1.59 trillion RMB in next 5 years, which would equal 1.3 times the annual government health expenditure in 2015.31

    • Utility of cystatin C-based equations in patients undergoing dialysis

      2018, Clinica Chimica Acta
      Citation Excerpt :

      RRT is a lifesaving treatment including dialysis and renal transplantation for people with ESRD [4]. Hemodialysis (HD), the major RRT in China, accounts for 80%–85% of patients [5], with a prevalence increasing from 49 per million population in 2006 to 83 per million population in 2008 [6]. What's more, the cost of dialysis treatment alone for one patient would be about $14,300 per year in China [6], posing a substantial burden on patients.

    • Chronic kidney disease: Global dimension and perspectives

      2013, The Lancet
      Citation Excerpt :

      The annual cost of dialysis treatment in China is around US$14 300 per patient. Although the Chinese Government plans to institute insurance schemes, patients in rural areas would still have to pay 35–45% of the cost, which will be prohibitive for most people.81 In India, the cost of a dialysis session varies from US$20 to $60, dependent on the type of facility.80

    • Prevalence of chronic kidney disease in China: A cross-sectional survey

      2012, The Lancet
      Citation Excerpt :

      For example, the prevalence of stage 3 chronic kidney disease was 1·6% in our study, compared with 7·7% in the USA and 4·2% in Norway. One explanation might be that hypertension and diabetes have increased rapidly in the past 15–20 years in China,21 but for these diseases to affect chronic kidney disease at a population level might take another 10 years.21 This lag provides a unique opportunity to slow the increase of chronic kidney disease prevalence caused by the changing epidemiology of hypertension and diabetes in China.

    View all citing articles on Scopus
    View full text